Twist Bioscience (TWST) is drawing fresh attention after a sharp move in its share price, with the stock up about 52% over the past month and about 98% over the past 3 months.
Twist Bioscience’s share price has surged in recent months, capped by a 51.8% 1‑month share price return and a 329.1% year to date share price return. Its 1 year total shareholder return of 415.4% points to strong momentum despite a small pullback over the past week.
Scan beyond Twist Bioscience’s surge and compare it with a curated set of fast moving growth stories across 19 high quality undiscovered gems.
After a move like this in Twist Bioscience, the temptation is to chase the trend while the worry is overpaying after a surge. So what does the current valuation actually say about buying now versus waiting?
Most Popular Narrative: 32% Overvalued
The most widely followed narrative for Twist Bioscience points to a fair value of $105.30 compared with the last close at $139. The gap reflects strong business expectations that, in this view, already look generously priced in.
Significant improvements in gross margin (now above 50%) through volume leverage, process improvements, and increased vertical integration signal ongoing margin expansion and a clear near-term path toward adjusted EBITDA breakeven, indicating robust future earnings potential.
Read the complete narrative. Read the complete narrative.
Want to know what kind of revenue path and margin profile sit behind that fair value? The narrative leans on fast top line expansion, rising profitability and a rich future earnings multiple. Curious how those moving parts combine into a single discounted value marker.
Result: Fair Value of $105.30 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still a risk that Twist Bioscience’s customer concentration and ongoing losses could trigger another capital raise, which could challenge this optimistic narrative.
Find out about the key risks to this Twist Bioscience narrative.
Another View: SWS DCF Points to Undervaluation
The analyst narrative suggests Twist Bioscience is about 32% overvalued relative to a $105.30 fair value. Our DCF model presents a different view. On that framework, Twist Bioscience at $139 is trading around 32% below an estimated future cash flow value of $205.57, which highlights a wide gap in expectations. Which set of assumptions appears more realistic to you?
To see how that cash flow based view is built and evaluate the inputs for yourself, take a closer look at the SWS DCF model behind this valuation. Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Twist Bioscience for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With such mixed signals around Twist Bioscience, it helps to move quickly and test the numbers yourself instead of relying on headlines alone. To get a balanced view of both the concerns and the potential upside, take a close look at the 2 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Twist Bioscience?
If Twist Bioscience has caught your attention, do not stop there. Broaden your watchlist with fresh ideas that match different goals and risk levels.
- Target potential mispriced opportunities by scanning for quality companies trading below implied value across 45 high quality undervalued stocks.
- Protect your downside by focusing on companies with resilient finances found through the 74 resilient stocks with low risk scores.
- Strengthen your core holdings by checking companies with sturdy finances and fundamentals using the list of solid balance sheet and fundamentals (52 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com